Value of gadoxetate biliary transit time in determining hepatocyte function

Area of Science:

• Radiology
• Hepatology
• Medical Imaging

Background:

• Hepatocellular function is crucial for liver health and disease assessment.
• Gadoxetate (Primovist) is a contrast agent used in MRI for liver imaging.
• Assessing liver function non-invasively is important for patient management.

Purpose of the Study:

• To investigate the correlation between gadoxetate excretion transit times in bile ducts and the duodenum with clinical models of hepatocellular function.
• To evaluate the utility of biliary excretion dynamics as a biomarker for liver function.

Main Methods:

• Retrospective analysis of 84 patients with chronic liver disease and 18 controls undergoing MRI with gadoxetate.
• Hepatobiliary phases were assessed at 10, 15, 20, and 25 minutes post-injection.
• Transit times for gadoxetate appearance in the biliary tree and duodenum were recorded.
• Linear trend analysis was used to correlate excretion times with Child-Pugh liver function classification.

Main Results:

• Gadoxetate arrival in the gallbladder was significantly earlier in controls than Child-Pugh A patients at 10 minutes.
• Biliary contrast transit times were significantly delayed in Child-Pugh B/C patients compared to Child-Pugh A patients.
• Delayed biliary transit times showed a significant correlation with worsening liver function (p = 0.01).
• No significant difference in gadoxetate entry time into the duodenum was observed across different liver function groups.

Conclusions:

• Biliary excretion transit time of gadoxetate is a reliable indicator of hepatocellular function.
• This metric may be valuable for inclusion in radiology reports for liver disease assessment.
• Duodenal excretion timing is influenced by factors beyond liver function, such as gallbladder and sphincter of Oddi physiology.